Skip to main navigation Skip to search Skip to main content

Perioperative Factor Xa Inhibitor Discontinuation for Patients Undergoing Procedures with Minimal or Low Bleeding Risk

  • So Ryoung Lee
  • , Kyung Yeon Lee
  • , Jong Sung Park
  • , Young Soo Lee
  • , Yong Seog Oh
  • , Sang Jin Han
  • , June Namgung
  • , Ji Hyun Lee
  • , Woo Hyun Lim
  • , Min Soo Ahn
  • , Soonil Kwon
  • , Hyo Jeong Ahn
  • , Seil Oh
  • , Gregory Y.H. Lip
  • , Eue Keun Choi
  • Seoul National University
  • Dong-A University
  • Catholic University of Daegu
  • Hallym University
  • Inje University
  • Seoul National University Boramae Hospital
  • Yonsei University Mirae Campus
  • University of Liverpool
  • Aalborg University
  • Liverpool John Moores University

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Importance: Discontinuation of oral anticoagulant treatment is common in clinical practice due to concerns about bleeding, even for procedures with minimal to low bleeding risk. Objective: To explore whether perioperative discontinuation of factor Xa inhibitors is associated with major bleeding and thromboembolic events in patients with atrial fibrillation (AF) undergoing procedures with minimal to low bleeding risk. Design, Setting, and Participants: This prospective, multicenter, single-arm cohort study conducted in Korea included patients with AF who planned to undergo a procedure with minimal to low bleeding risk between September 25, 2020, and April 5, 2024. Exposure: The PERIXa (Perioperative Factor Xa Inhibitor Discontinuation in Patients With Atrial Fibrillation Undergoing Minimal to Low Bleed Risk Procedures) protocol recommending giving the last dose of factor Xa inhibitor (ie, apixaban, edoxaban, or rivaroxaban) 24 hours before the procedure (ie, endoscopy, dental procedure, or ocular surgery) and restarting treatment with the inhibitor the next day. Main Outcomes and Measures: The primary outcome was major bleeding, and the secondary outcome included a composite of thromboembolic events 30 days after the index procedure with minimal to low bleeding risk. Results: In total, 1902 patients were included in the modified intention-to-treat analysis set encompassing all patients who underwent the intended procedure (mean [SD] age, 70.4 [8.8] years; 1135 [59.7%] male; mean [SD] CHA2DS2-VASc [congestive heart failure, hypertension, age 75 years or older, diabetes, stroke, vascular disease, age 65-74 years, and female sex; range, 0-9, with higher scores indicating higher risk of stroke] score, 2.8 [1.3]; mean [SD] HAS-BLED [hypertension, kidney or liver disease, stroke history, prior bleeding, unstable international normalized ratio, age >65 years, and drug or alcohol use; range, 0-9, with higher scores indicating higher risk of bleeding] score, 1.6 [0.7]). Among them, 921 (48.4%) were receiving apixaban, 616 (32.4%) were receiving edoxaban, and 365 (19.2%) were receiving rivaroxaban. Of the total procedures, 948 (49.8%) were endoscopy, 820 (43.1%) were dental procedures, and 120 (6.3%) were ocular surgery. The 30-day event rate of major bleeding was 0.1% (n = 2), and there were no composite thromboembolic events. The results were consistent in the per-protocol analysis, and no differences were observed by procedure category or factor Xa inhibitor type. Conclusions and Relevance: In this cohort study, patients with AF receiving a factor Xa inhibitor and undergoing a procedure with minimal to low bleeding risk had low rates of major bleeding and thromboembolism when following the standardized PERIXa protocol for perioperative management of oral anticoagulant treatment, suggesting that this may be a safe and reasonable option for this patient population.

Original languageEnglish
Pages (from-to)e2458742
JournalJAMA network open
Volume8
Issue number2
DOIs
StatePublished - 7 Feb 2025

Bibliographical note

Publisher Copyright:
© 2025 Lee SR et al. JAMA Network Open.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Perioperative Factor Xa Inhibitor Discontinuation for Patients Undergoing Procedures with Minimal or Low Bleeding Risk'. Together they form a unique fingerprint.

Cite this